MMCM
MRNA icon

Murphy & Mullick Capital Management’s Moderna MRNA Stock Holding History

Murphy & Mullick Capital Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.73K Sell
139
-2
-1% -$103 0.01% 493
2026
Q1 		$7.16K Sell
141
-88
-38% -$4.11K 0.01% 508
2025
Q4 		$6.75K Sell
229
-21
-8% -$571 ﹤0.01% 522
2025
Q3 		$6.46K Sell
250
-69
-22% -$1.93K ﹤0.01% 518
2025
Q2 		$9.43K Sell
319
-259
-45% -$6.82K 0.01% 467
2025
Q1 		$16.4K Hold
578
– – 0.02% 387
2024
Q4 		$24K Buy
+578
New +$27.6K 0.02% 335

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Murphy & Mullick Capital Management's MRNA Position: Q2 2026 in Review

Murphy & Mullick Capital Management reduced its Moderna (MRNA) stake by 1.4% in Q2 2026, selling an estimated $103 and leaving 139 shares worth $9.73K. The position accounts for 0.01% of the portfolio, ranked #493.

Murphy & Mullick Capital Management first reported a position in MRNA in Q4 2024 and has held it in 7 quarters since. The position peaked at $24K in Q4 2024. 780 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Murphy & Mullick Capital Management held 139 shares of Moderna worth $9.73K as of Q2 2026.
  • Murphy & Mullick Capital Management sold 2 Moderna shares in Q2 2026, an estimated $103.
  • Moderna made up 0.01% of Murphy & Mullick Capital Management's portfolio in Q2 2026, its #493 holding.
  • Murphy & Mullick Capital Management first reported a position in Moderna in Q4 2024 and has held it in 7 quarters since.
  • Murphy & Mullick Capital Management's Moderna position peaked at $24K in Q4 2024.
  • 780 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Murphy & Mullick Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.